Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

华盛顿大学参与者参与和癌症基因组测序中心 (WU-PE-CGS)

• 批准号: 10759096
• 负责人: GRAHAM A. COLDITZ
• 金额: $ 0.44万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10759096
• 关键词: Acceleration; Address; Advocacy; Aftercare; Age; CLIA certified; Cancer Patient; Cancer Survivor; Capital; Characteristics; Cholangiocarcinoma; Colorectal Cancer; Communication; Communities; Complex; Creativeness; Development; Disadvantaged; Discipline; Disparity; Ensure; Environment; Evaluation; Family; Fostering; Genomics; Goals; Health Benefit; Health system; Investments; Knowledge; Leadership; Malignant Neoplasms; Methodology; Multiple Myeloma; Participant; Patient advocacy; Patients; Persons; Population; Positioning Attribute; Provider; Research; Research Personnel; Resources; Rural Population; Science; Technology; Testing; Underserved Population; Universities; Vision; Washington; anticancer research; cancer genomics; cancer health disparity; career; evidence base; follow-up; genome sequencing; improved; innovation; interdisciplinary collaboration; member; outreach; patient engagement; patient oriented; patient population; rare cancer; recruit; success; synergism; tumor; understudied cancer

PROJECT SUMMARY Vision. Participant engagement and sequencing research from the Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) will fill critical gaps in knowledge, methodology, and characterization of understudied cancer populations, leading to optimal approaches to participant engagement, outreach, and communication in genomic characterization studies. Goal. The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research. Our focus is on rare and understudied cancer populations with significant disparities including cholangiocarcinoma, multiple myeloma, and colorectal cancer under age 50. Participant engagement strategies are most effective when they are adapted and implemented in real-world settings in partnership with community and patient advocacy stakeholders. Setting. Our Center will be housed in an exceptional environment that fosters transdisciplinary collaboration, catalyzes new ideas in patient engagement, and ensures support for patient engagement and genome sequencing that finds solutions for complex recruitment and engagement challenges in real-world settings with underrepresented patient populations. Significant matching contributions from Washington University will allow us to quickly and strategically invest in ideas. Aims. The specific aims of the Center are to: (1) Advance the field of participant engagement to study cancer disparities and rare cancers by conducting innovative and impactful direct stakeholder engagement with continuous evaluation and research; (2) Expand an exceptional, diverse team of investigators, patients, and advocacy stakeholders; (3) Address cancer disparities by understanding barriers to and improving the ability for disadvantaged and understudied populations to encounter, use, and benefit from genomic sequencing and analysis; (4) Organize and integrate Center units to facilitate transdisciplinary, team science within our Center and across the PE-CGS Network. Innovations and impact. The WU-PE-CGS builds on a long and outstanding record of leadership in both cancer disparities and genomic research across the cancer continuum. We will be particularly innovative and allow for a significant return on the scientific investment in several ways. First, our Center has distinctive features that include a combined focus on cancer disparities, the application of strategies to increase participant engagement in research, success in biospecimen acquisition, and exceptional genomic sequencing expertise. Second, we have assembled a diverse, world class team with strong linkages to multiple rare and understudied cancers. Third, we engage investigators from different disciplines and invest in the development of early career scholars. Fourth, we will strategically and creatively disseminate products in ways that will benefit researchers, practitioners, and community members. Fifth, we will partner with exceptional patient-centered and wide-reaching advocacy groups to engage patients, optimize recruitment, and seamlessly return results. Input from these groups, patients, and their families is a key strength that will leverage our track record of stakeholder-engaged research. And finally, we have developed a focused strategy for collective integration of our units. These synergies will allow our Center to become a national resource for optimal approaches to participant engagement, outreach, and communication in genomic characterization studies and other studies as technologies advance that will accelerate progress for both the scientific community, patients and their communities. In summary, we are uniquely situated to advance a network of participant engagement and sequencing researchers, integrate research with patients and their stakeholders, build intellectual capital, and significantly enhance the capacity for participant engagement and genomic characterization studies. This Center will ultimately benefit health systems, providers, and people with rare cancers and lead to a reduction in cancer disparities.

项目概要 想象。华盛顿大学参与者的参与者参与和排序研究 参与和癌症基因组测序中心 (WU-PE-CGS) 将填补知识、 方法论以及未充分研究的癌症人群的特征，从而找到最佳方法 基因组表征研究中的参与者参与、推广和交流。 目标。 WU-PE-CGS 的总体目标是为直接方法建立严格、科学的证据基础 让癌症患者和治疗后癌症幸存者参与癌症研究。我们的 重点是具有显着差异的罕见和未充分研究的癌症人群，包括胆管癌、 多发性骨髓瘤和 50 岁以下结直肠癌。参与者参与策略最有效 当它们与社区和患者合作在现实环境中进行调整和实施时 倡导利益相关者。 环境。我们的中心将坐落在一个促进跨学科合作的特殊环境中， 促进患者参与的新想法，并确保对患者参与和基因组的支持 排序，为现实环境中复杂的招聘和参与挑战找到解决方案 患者群体代表性不足。华盛顿大学的重大配套贡献将允许 我们能够快速、战略性地投资创意。 目标。该中心的具体目标是： (1) 推进参与者参与癌症研究的领域 通过与利益相关者进行创新和有影响力的直接接触来消除差异和罕见癌症 持续评估和研究； (2) 扩大一支由研究者、患者和患者组成的卓越、多元化的团队 倡导利益相关者； (3) 通过了解障碍并提高能力来解决癌症差异 让弱势群体和未充分研究的人群能够接触、使用基因组测序并从中受益 分析; (4) 组织和整合中心各单位，以促进中心内的跨学科、团队科学 以及整个 PE-CGS 网络。 创新和影响。 WU-PE-CGS 建立在癌症和癌症领域长期杰出的领导记录之上 整个癌症连续体的差异和基因组研究。我们将特别创新并允许 通过多种方式获得科学投资的显着回报。一、我中心具有鲜明的特色 包括综合关注癌症差异、应用策略来增加参与者 参与研究、成功获取生物样本以及卓越的基因组测序专业知识。 其次，我们组建了一支多元化的世界级团队，与多个稀有和未被充分研究的物种有着密切的联系。 癌症。第三，我们聘请不同学科的研究人员并投资早期的开发 职业学者。第四，我们将有策略地、创造性地以有利的方式传播产品 研究人员、从业者和社区成员。第五，我们将与以患者为中心的杰出人士合作 以及影响广泛的倡导团体来吸引患者、优化招募并无缝返回结果。 这些团体、患者及其家人的意见是一个关键优势，将利用我们的跟踪记录 利益相关者参与的研究。最后，我们制定了集体整合的重点战略 我们的单位。这些协同作用将使我们的中心成为最佳方法的国家资源 基因组表征研究和其他研究中的参与者参与、推广和交流 随着技术的进步，将加速科学界、患者及其家属的进步 社区。 总之，我们具有独特的优势来推进参与者参与和排序网络 研究人员将研究与患者及其利益相关者整合起来，建立智力资本，并显着 提高参与者参与和基因组表征研究的能力。该中心将 最终使卫生系统、医疗服务提供者和罕见癌症患者受益，并减少癌症发病率 差异。

项目成果

Cell-Free DNA Liquid Biopsy: The Epitome of Personalized Precision Oncology.

无细胞 DNA 液体活检：个性化精准肿瘤学的缩影。

• DOI: 10.1667/rade-23-00044.1
• 发表时间: 2023
• 期刊: Radiation research
• 影响因子: 3.4
• 作者: Chaudhuri,AadelA

High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival.

• DOI: 10.1038/s41698-023-00455-z
• 发表时间: 2023-10-19
• 期刊: NPJ precision oncology
• 影响因子: 7.9

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.

放疗前 ctDNA 液体活检用于寡转移非小细胞肺癌的风险分层。

• DOI: 10.21203/rs.3.rs-2688927/v1
• 发表时间: 2023
• 期刊: Research square
• 作者: Semenkovich,NicholasP;Samson,PamelaP;Badiyan,ShahedN;Vlacich,Gregory;Stowe,HayleyB;Wang,YunE;Star,Rachel;Devarakonda,Siddhartha;Govindan,Ramaswamy;Waqar,SaiamaN;Robinson,CliffordG;Pellini,Bruna;Chaudhuri,AadelA
• 通讯作者: Chaudhuri,AadelA